Subcutaneous dupilumab significantly reduced the use of oral corticosteroids in patients with corticosteroid-dependent severe asthma.
Compared to the control group, patients who took four or more oral corticosteroid prescriptions had 1.29 times the odds of experiencing a new adverse effect within the year.
Drugs in the Pipeline
Treatment with masitinib, a selective tyrosine kinase inhibitor, significantly reduces the rate of severe asthma exacerbations in patients with severe asthma uncontrolled by oral corticosteroids, according to data from a phase 3 study.
Treatment with mepolizumab was associated with a significant reduction in asthma exacerbations and oral corticosteroid use in patients with severe eosinophilic asthma.
In the asthma clinical trials, the most common adverse reactions were injection site reactions, oropharyngeal pain, and eosinophilia.
Peak expiratory flow increases were greater with benralizumab than placebo in patients with severe eosinophilic asthma.
The data revealed the most common indications for short-term corticosteroid use to be upper respiratory tract infections, spinal conditions, and allergies.
Fasenra is indicated for the add-on maintenance treatment of patients with severe asthma aged 12 years and older, and with an eosinophilic phenotype.
The authors reported that ACQ scores (P=0.04) and oral corticosteroid use (P=0.04) were significantly reduced in high severity completers (n=21) receiving escitalopram.
The first-in-class tyrosine kinase inhibitor masitinib decreased asthma exacerbations greater than placebo in patients with severe asthma uncontrolled by oral corticosteroids.